TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis. [electronic resource]
Producer: 20130520Description: 501-8 p. digitalISSN:- 1534-6307
- Adalimumab
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis -- drug therapy
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antirheumatic Agents -- adverse effects
- Etanercept
- Granulomatosis with Polyangiitis -- drug therapy
- Humans
- Immunoglobulin G -- adverse effects
- Infliximab
- Neoplasms -- epidemiology
- Receptors, Tumor Necrosis Factor
- Risk Factors
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.